China’s Ministry of Commerce building in Beijing, May 23, 2023. File photo, not the current policy announcement. EditQ / Wikimedia Commons · CC BY-SA 4.0. Original unaltered; display crop.
By E.K.K
China has proposed export controls covering 40 technologies, with registration requirements already taking effect. Asian businesses need to establish whether a deal buys a product, provides access to a service or transfers technical capability. That distinction could determine what paperwork a partnership requires.
Registration comes before the final rules
The October 16 proposal covers AI, biotechnology and solar manufacturing. The consultation runs through November 15. Proposed prohibitions and restrictions should not be confused with rules that have all entered into force.
Registration is already required for covered exports, including transactions underway but not completed. A signed agreement therefore does not, by itself, settle the compliance question.
What a partner actually receives matters
A technology transfer can involve intellectual property or permission to use a process abroad. For a manufacturer, the commercial value may lie in being able to operate, repair and improve a production line over time.
The commerce ministry says the proposed framework includes exclusions and facilitation measures. Publicly available open-source technology and some ways of accessing AI services are treated differently from transferring controlled technology. The label “Chinese AI” is too broad to establish how a particular transaction would be handled.
Costs may arise before a deal is stopped
Our assessment is that the immediate commercial issue is planning: partners need to identify covered know-how, prepare documentation and allocate responsibility for delays. There is not yet enough evidence to put a regional price tag on those costs.
Seeking another supplier is an option, but replacing a process can require testing, training and fresh investment. A restriction on one provider does not automatically make a competitor an adequate substitute.
Beijing presents the proposal as a security measure. Retaining control of valuable technology also has industrial advantages, although cumbersome procedures could discourage overseas adoption. Those incentives pull in different directions.
AI: access and control are different purchases
Consider an Asian business adopting a Chinese AI system. Accessing a model over a network is commercially different from receiving technology that it can operate on its own infrastructure. The ministry’s explanation distinguishes between forms of overseas use; the details of the delivery matter.
For a bank, hospital or manufacturer, the arrangement also determines where data sits, who can repair a failure and what happens if a provider withdraws service. A company may still have access to AI while possessing less independent operating capability than it originally intended to acquire.
This is an analysis of possible contract consequences, not evidence that those sectors have already been required to renegotiate. A project must be assessed against its actual technology and delivery terms.
Solar: a factory needs more than a shipment
Purchasing finished solar products and acquiring a manufacturing process serve different purposes. The latter can support local engineering skills, employment and future production capabilities.
If a project depends on controlled know-how, investors must consider installation, commissioning and upgrades alongside the equipment itself. A completed building cannot generate the expected return while a critical production step remains unavailable. That is a potential investment risk, not a documented shutdown caused by this proposal.
For Asian governments seeking local manufacturing, the question therefore extends beyond whether a factory moves. Which capabilities become available locally, and which remain with an overseas provider? Assembly capacity alone does not establish the ability to improve the underlying process.
Biotechnology: what does the licence cover?
Permission to use technology is distinct from ownership of the platform behind it. The ministry describes exceptions or simplified treatment for some licensing and outsourced research arrangements. Adding biotechnology categories does not establish a blanket stop to international development work.
A partner needs to understand whether a licence extends to later development, manufacturing and improvements. Limited rights may still be commercially valuable, but expanding an application could require another negotiation. The scope affects both the promises a company can make and its continuing dependence on the original provider.
The burden will not be shared evenly
Larger businesses generally have more resources to compare technologies, obtain specialist advice and develop alternative suppliers. A smaller company dependent on one partner may find uncertainty harder to absorb. Approval eventually arriving does not erase time and money spent waiting.
Chinese providers have interests at stake too. Overseas customers supply revenue, feedback and opportunities to expand adoption. Procedures that make cooperation less attractive can cost suppliers business. Whether simplified arrangements work in practice will influence the balance between retaining control and developing markets.
Consumers should not assume that AI subscriptions, medicines or electricity will automatically become more expensive. Competition, inventories, substitute technologies and firms’ willingness to absorb costs all stand between a technology transaction and a retail bill. Evidence of changed contracts or investment should come before claims about household prices.
Watch implementation
The useful indicators are changes to the final scope, the operation of simplified procedures and documented effects on actual projects. Until those emerge, claims of a wholesale technology shutdown go beyond the evidence.